1.806SEK-0.22%Mkt Cap: 688.35M SEKP/E: —Last update: 2026-06-01
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap688.35M SEK
Enterprise Value419.24M SEK
Revenue (TTM)83.23M SEK
Gross Profit68.67M SEK
Net Income (TTM)-249.59M SEK
Revenue/Share0.3130 SEK
Last Price1.806 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees75
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009414576
Valuation
P/E (Trailing)—
P/E (Forward)-2.55
PEG—
EV/EBITDA-2.08
EV/Revenue5.04
P/S8.29
P/B-8.38
EPS (TTM)-0.87
EPS (Forward)-0.71
52W Range
1.2659% of range6.960
52W High6.960 SEK
52W Low1.265 SEK
Profitability
Gross Margin96.55%
Oper. Margin-147.85%
EBITDA Margin-241.61%
Profit Margin-350.94%
ROE423.81%
ROA-184.33%
Growth
Revenue Growth91.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-222.88M SEK
CapEx (TTM)—
FCF Margin-144.89%
FCF Yield-17.52%
Net Debt-74.35M SEK
Net Debt/EBITDA0.37
Balance Sheet
Debt/Equity-2.37
Current Ratio4.55
Quick Ratio4.38
Book Value/Sh-0.2160 SEK
Cash/Share0.7520 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)2.600 SEK
Target Range2.100 SEK – 3.100 SEK
# Analysts2
Ownership
Shares Out.381.15M
Float261.70M
Insiders9.05%
Institutions9.36%
Technical
SMA 501.480 (+22.0%)
SMA 2003.549 (-49.1%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)11.48M
Avg Vol (10d)18.10M
Technical Indicators
RSI (14)56.6
MACD0.1234
MACD Signal0.0906
MACD Hist.+0.0328
BB Upper2.178 SEK
BB Middle1.607 SEK
BB Lower1.036 SEK
BB Width71.04%
ATR (14)0.2097 SEK
Vol Ratio (20d)0.55x